195 related articles for article (PubMed ID: 37890355)
1. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2023.
Latzka J; Assaf C; Bagot M; Cozzio A; Dummer R; Guenova E; Gniadecki R; Hodak E; Jonak C; Klemke CD; Knobler R; Morrris S; Nicolay JP; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Wehkamp U; Whittaker S; Willemze R; Trautinger F
Eur J Cancer; 2023 Dec; 195():113343. PubMed ID: 37890355
[TBL] [Abstract][Full Text] [Related]
2. European Organisation for Research and Treatment of Cancer consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome - Update 2017.
Trautinger F; Eder J; Assaf C; Bagot M; Cozzio A; Dummer R; Gniadecki R; Klemke CD; Ortiz-Romero PL; Papadavid E; Pimpinelli N; Quaglino P; Ranki A; Scarisbrick J; Stadler R; Väkevä L; Vermeer MH; Whittaker S; Willemze R; Knobler R
Eur J Cancer; 2017 May; 77():57-74. PubMed ID: 28365528
[TBL] [Abstract][Full Text] [Related]
3. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part II. Prognosis, management, and future directions.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):223.e1-17; quiz 240-2. PubMed ID: 24438970
[TBL] [Abstract][Full Text] [Related]
4. EORTC consensus recommendations for the treatment of mycosis fungoides/Sézary syndrome.
Trautinger F; Knobler R; Willemze R; Peris K; Stadler R; Laroche L; D'Incan M; Ranki A; Pimpinelli N; Ortiz-Romero P; Dummer R; Estrach T; Whittaker S
Eur J Cancer; 2006 May; 42(8):1014-30. PubMed ID: 16574401
[TBL] [Abstract][Full Text] [Related]
5. Mycosis Fungoides and Sézary Syndrome: Updates and Review of Current Therapy.
Kamijo H; Miyagaki T
Curr Treat Options Oncol; 2021 Jan; 22(2):10. PubMed ID: 33415447
[TBL] [Abstract][Full Text] [Related]
6. How I treat mycosis fungoides and Sézary syndrome.
Whittaker S; Hoppe R; Prince HM
Blood; 2016 Jun; 127(25):3142-53. PubMed ID: 27151889
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
8. Primary cutaneous T-cell lymphomas other than mycosis fungoides and Sézary syndrome. Part II: Prognosis and management.
Oh Y; Stoll JR; Moskowitz A; Pulitzer M; Horwitz S; Myskowski P; Noor SJ
J Am Acad Dermatol; 2021 Nov; 85(5):1093-1106. PubMed ID: 33945836
[TBL] [Abstract][Full Text] [Related]
9. Mycosis fungoides and Sézary syndrome.
Jonak C; Tittes J; Brunner PM; Guenova E
J Dtsch Dermatol Ges; 2021 Sep; 19(9):1307-1334. PubMed ID: 34541796
[TBL] [Abstract][Full Text] [Related]
10. Primary cutaneous T-cell lymphoma (mycosis fungoides and Sézary syndrome): part I. Diagnosis: clinical and histopathologic features and new molecular and biologic markers.
Jawed SI; Myskowski PL; Horwitz S; Moskowitz A; Querfeld C
J Am Acad Dermatol; 2014 Feb; 70(2):205.e1-16; quiz 221-2. PubMed ID: 24438969
[TBL] [Abstract][Full Text] [Related]
11. Cost-utility analysis of mogamulizumab in advanced mycosis fungoides and Sézary syndrome cutaneous T-cell lymphoma.
Muszbek N; Remak E; Xin Q; McNamara L; Jones T
J Comp Eff Res; 2023 Jul; 12(7):CER. PubMed ID: 37338181
[No Abstract] [Full Text] [Related]
12. Mycosis fungoides and Sézary syndrome: focus on the current treatment scenario.
Sanches JA; Cury-Martins J; Abreu RM; Miyashiro D; Pereira J
An Bras Dermatol; 2021; 96(4):458-471. PubMed ID: 34053802
[TBL] [Abstract][Full Text] [Related]
13. New nonchemotherapy treatment options for cutaneous T-cell lymphomas.
Xu S; Foss F
Expert Rev Anticancer Ther; 2021 Sep; 21(9):1017-1028. PubMed ID: 33554707
[TBL] [Abstract][Full Text] [Related]
14. How we treat advanced stage cutaneous T-cell lymphoma - mycosis fungoides and Sézary syndrome.
Sethi TK; Montanari F; Foss F; Reddy N
Br J Haematol; 2021 Nov; 195(3):352-364. PubMed ID: 33987825
[TBL] [Abstract][Full Text] [Related]
15. Are we there yet? cellular therapies for cutaneous T cell lymphoma.
Atilla PA; Atilla E
Curr Res Transl Med; 2023; 71(2):103390. PubMed ID: 37062252
[TBL] [Abstract][Full Text] [Related]
16. Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.
Photiou L; van der Weyden C; McCormack C; Miles Prince H
Curr Oncol Rep; 2018 Mar; 20(4):32. PubMed ID: 29572582
[TBL] [Abstract][Full Text] [Related]
17. Current systemic therapeutic options for advanced mycosis fungoides and Sézary syndrome.
Janiga J; Kentley J; Nabhan C; Abdulla F
Leuk Lymphoma; 2018 Mar; 59(3):562-577. PubMed ID: 29308723
[TBL] [Abstract][Full Text] [Related]
18. Brentuximab as a treatment for CD30+ mycosis fungoides and Sézary syndrome.
Mehra T; Ikenberg K; Moos RM; Benz R; Nair G; Schanz U; Haralambieva E; Hoetzenecker W; Dummer R; French LE; Guenova E; Cozzio A
JAMA Dermatol; 2015 Jan; 151(1):73-7. PubMed ID: 25317818
[TBL] [Abstract][Full Text] [Related]
19. Leukaemic variants of cutaneous T-cell lymphoma: Erythrodermic mycosis fungoides and Sézary syndrome.
Martinez XU; Di Raimondo C; Abdulla FR; Zain J; Rosen ST; Querfeld C
Best Pract Res Clin Haematol; 2019 Sep; 32(3):239-252. PubMed ID: 31585624
[TBL] [Abstract][Full Text] [Related]
20. Efficacy and tolerability of currently available therapies for the mycosis fungoides and Sezary syndrome variants of cutaneous T-cell lymphoma.
Whittaker SJ; Foss FM
Cancer Treat Rev; 2007 Apr; 33(2):146-60. PubMed ID: 17275192
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
